Manual_digital

251 / 510

Cuidados
Continuos
250
BIBLIOGRAFIA
Sahn SA. Pleural effusions of extravascular origin. Clin Chest Med. 2006;27(2):285-308
Van de Molengraft FJ, Vooijs GP. Survival of patients with malignancy-associated effusions.
Acta Cytol 1989;33:911-16.
Porcel JM, Vives M. Etiology and pleural fluid characteristics of large and massive effusions.
Chest. 2003; 124(3):978-983
Pilling JE, Dusmet ME, Ladas G, Goldstraw P. Prognostic factors for survival after surgical
palliation of malignant pleural effusion. J Thorac Oncol 2010; 5:1544
Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural
effusions. Mayo Clin Proc 2008; 83:235.
Pulmón no expansible Marco F. Pereyra, Lucía Ferreiro y Luis Valdés. Arch Bronconeumol.
2013; 49(2):63–69)
Mark E Roberts et. al, on behalf of the BTS Pleural Disease Guideline Group. British Thoracic
Society pleural disease guideline 2010. Thorax 2010;65(Suppl 2):ii32eii40.
Davies HE, Mishra EK, Kahan BC, et al. Effect of an Indwelling Pleural Catheter vs Chest
Tubeand Talc Pleurodesis for Relieving Dyspnea in Patients With Malignant Pleural Effusion:
JAMA.2012; 307:2382-9.
Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchinson JG. The serum-
ascites albumin gradient is superior to the exudate-transudate concept in the differential
diagnosis of ascites. Ann Intern Med 1992; 117:215-20.
Giannini EG, Marabotto E, Savarino V, Trevisani F, di NolfoMA, Del Poggio P, et al. Hepatocellular
carcinoma in patients with cryptogenic cirrhosis. Clin Gastroenterol Hepatol 2009; 7:580-5.
Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites.
Hepatology 1988; 8:1104-9.
Decker D, Stratmann H, Springer W, Schwering H, Varnay N, Bollmann N. Benign and
malignant cells in effusions: diagnostic value of image DNA cytometry in comparison to
cytological analysis. Pathol Res Pract 1998; 194:791-5
Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519-29
Heiss MM, Murawa P, Koralewsky P, Kutarska E, Kolesnik OO, Ivanchenko VV et al. The
trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial
cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 2010; 127:2209-21
Yeh EH, Bickford CL, Ewer MS. Chapter 90. The Diagnosis and Management of Cardiovascular
Disease in Patients with Cancer.En: Hurst’s The Heart, 13e. Editado por Fuster V, Walsh RA,
Harrington RA. New York, NY: McGraw-Hill; 2011. Acceso 27 de Marzo de 2014:
Refaat MM , Katz WE. Neoplastic Pericardial Effusion. Clin. Cardiol. 2011; 34(10): 593–598.
Burazor I, Imazio M, Markel G, Adler Y. Malignant pericardial effusion. Cardiology.
2013;124(4):224-32.
Lamont EB, Hoffman PC. Chapter 72. Oncologic Emergencies. En: Principles of Critical Care, 3e.
Editado por Hall JB, Schmidt GA, Wood LH.New York, NY: McGraw-Hill; 2005. Acceso 28 de Marzo
de 2014:
The Task Force on the Diagnosis and Management of Pericardial Diseases of the European
Society of Cardiology. Guidelines on the Diagnosis and Management of Pericardial Diseases
Full Text. European Heart Journal.2004: 1–28
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.